These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 6282189)
21. [Arterial hypertension. Physiopathologic approach by means of the renin-angiotensin-aldosterone and kallikrein-kinin-prostaglandin systems]. Antón Aranda E; Martí Cabane J; Tiberio López G Rev Clin Esp; 1983 Jun 15-30; 169(5-6):287-91. PubMed ID: 6555850 [No Abstract] [Full Text] [Related]
22. Converting enzyme inhibitors normalize the reduced adrenal responsiveness to angiotensin II in essential hypertension. Williams GH; Hollenberg NK J Hypertens Suppl; 1984 Dec; 2(2):S43-7. PubMed ID: 6100876 [TBL] [Abstract][Full Text] [Related]
23. [Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists]. Asmar R; Madonna O; Brisac AM; Benetos A; Laurent S Therapie; 1998; 53(3):253-70. PubMed ID: 9773125 [TBL] [Abstract][Full Text] [Related]
24. [Studies on the mechanism of action of angiotensin converting enzyme inhibitors on the dog kidney]. Omosu M Nihon Jinzo Gakkai Shi; 1992 Aug; 34(8):883-94. PubMed ID: 1484407 [TBL] [Abstract][Full Text] [Related]
26. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
27. Effects of two structurally different angiotensin-converting enzyme inhibitors, captopril and quinapril (CI-906), in rats with one-kidney deoxycorticosterone-salt hypertension. Pörsti I; Säynävälammi P; Arvola P; Nurmi AK; Manninen V; Ylitalo P; Vapaatalo H Methods Find Exp Clin Pharmacol; 1986 Sep; 8(9):543-6. PubMed ID: 3022083 [TBL] [Abstract][Full Text] [Related]
28. [Effects of angiotensin converting enzyme inhibitor SQ 14,225 on the blood pressure, renin-angiotensin-aldosterone system and renal function in patients with malignant hypertension (author's transl)]. Shionoiri H; Uneda S; Tochikubo O; Ohonishi T; Harada J; Sesoko S; Goto E; Fujishima S; Kaneko Y Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):13-22. PubMed ID: 6247528 [No Abstract] [Full Text] [Related]
29. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046 [TBL] [Abstract][Full Text] [Related]
30. Endocrine mechanisms in the pathogenesis of essential hypertension. III. Special reference on the interrelations between the prostaglandin and kallikrein-kinin systems. Păuşescu E Physiologie; 1981; 18(2):141-52. PubMed ID: 6791173 [TBL] [Abstract][Full Text] [Related]
31. [What have we learned about inhibitors of the renin-angiotensin system?]. Waeber B; Nussberger J; Brunner HR Ann Endocrinol (Paris); 1986; 47(3):167-77. PubMed ID: 3022638 [TBL] [Abstract][Full Text] [Related]
32. Circulatory basis for the use of angiotensin converting enzyme inhibitors in hypertension and cardiac failure. Robertson JI J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S2-8. PubMed ID: 2422488 [TBL] [Abstract][Full Text] [Related]
33. Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition. Overlack A; Stumpe KO; Kühnert M; Kolloch R; Ressel C; Heck I; Krück F Klin Wochenschr; 1981 Jan; 59(2):69-74. PubMed ID: 6163004 [TBL] [Abstract][Full Text] [Related]